Sophiris Bio Inc.
(NASDAQ : SPHS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
0.17%358.711.2%$830.53m
AMGNAmgen Inc.
-0.66%190.491.2%$543.11m
CELGCelgene Corporation
-0.28%85.101.2%$507.54m
GILDGilead Sciences, Inc.
0.42%77.370.9%$473.45m
VRTXVertex Pharmaceuticals Incorporated
-1.51%177.401.9%$313.54m
REGNRegeneron Pharmaceuticals, Inc.
-0.17%367.112.6%$276.88m
ILMNIllumina, Inc.
0.66%311.153.5%$269.38m
BLUEBluebird Bio, Inc.
0.78%180.3515.7%$197.52m
SRPTSarepta Therapeutics, Inc.
-1.64%133.3116.6%$196.81m
ALXNAlexion Pharmaceuticals, Inc.
0.05%135.162.0%$178.57m
NKTRNektar Therapeutics
-0.71%48.735.6%$172.03m
EXASExact Sciences Corporation
0.02%67.6225.4%$155.70m
EXELExelixis, Inc.
-0.23%21.296.4%$135.36m
BMRNBioMarin Pharmaceutical Inc.
-0.94%101.904.4%$122.64m
AAgilent Technologies, Inc.
-0.45%63.861.5%$110.57m

Company Profile

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. It is currently developing PRX302 as a treatment for the symptoms of benign prostatic hyperplasia which is a non cancerous enlargement of the prostate gland that causes a restriction in urine flow from the urethra resulting in lower urinary tract symptoms. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.